These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 9403859)
1. Neuroprotective effects of functional antagonists at the glycine site of the NMDA receptor. Trullas R Methods Find Exp Clin Pharmacol; 1997; 19 Suppl A():55-6. PubMed ID: 9403859 [No Abstract] [Full Text] [Related]
2. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor mediates xenon neuroprotection against hypoxia-ischemia. Banks P; Franks NP; Dickinson R Anesthesiology; 2010 Mar; 112(3):614-22. PubMed ID: 20124979 [TBL] [Abstract][Full Text] [Related]
3. Dantrolene antagonizes the glycineB site of the NMDA receptor. Salinska E; Sobczuk A; Lazarewicz JW Neurosci Lett; 2008 Feb; 432(2):137-40. PubMed ID: 18191027 [TBL] [Abstract][Full Text] [Related]
4. L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective. Priestley T; Marshall GR; Hill RG; Kemp JA Br J Pharmacol; 1998 Aug; 124(8):1767-73. PubMed ID: 9756395 [TBL] [Abstract][Full Text] [Related]
6. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist of N-methyl-D-aspartate receptor GV196771A. Quartaroli M; Carignani C; Dal Forno G; Mugnaini M; Ugolini A; Arban R; Bettelini L; Maraia G; Belardetti F; Reggiani A; Trist DG; Ratti E; Di Fabio R; Corsi M J Pharmacol Exp Ther; 1999 Jul; 290(1):158-69. PubMed ID: 10381772 [TBL] [Abstract][Full Text] [Related]
7. LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy. Potschka H; Löscher W; Wlaź P; Behl B; Hofmann HP; Treiber HJ; Szabo L Br J Pharmacol; 1998 Nov; 125(6):1258-66. PubMed ID: 9863655 [TBL] [Abstract][Full Text] [Related]
8. Novel antagonists of the inhibitory glycine receptor derived from quinolinic acid compounds. Schmieden V; Jezequel S; Betz H Mol Pharmacol; 1996 Nov; 50(5):1200-6. PubMed ID: 8913351 [TBL] [Abstract][Full Text] [Related]
12. [Modern aspects of investigation and clinical application of glutamatergic agents]. Petrov VI; Onishchenko NV Eksp Klin Farmakol; 2002; 65(4):66-70. PubMed ID: 12449079 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers. Hu LY; Guo J; Magar SS; Fischer JB; Burke-Howie KJ; Durant GJ J Med Chem; 1997 Dec; 40(26):4281-9. PubMed ID: 9435897 [TBL] [Abstract][Full Text] [Related]
14. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Lipton SA Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917 [TBL] [Abstract][Full Text] [Related]
15. Potentiation of the NMDA receptor-mediated responses through the activation of the glycine site by microglia secreting soluble factors. Hayashi Y; Ishibashi H; Hashimoto K; Nakanishi H Glia; 2006 Apr; 53(6):660-8. PubMed ID: 16498631 [TBL] [Abstract][Full Text] [Related]